Analysis of the Development and State Regulation of Pharmaceutical Companies in the Republic of Kazakhstan

Main problem: In Kazakhstan, the pharmaceutical market is one of the most developed in the CIS countries. To a certain extent, the shortage has been overcome and saturation with various types of finished medicines and medical products has been ensured. The service culture has increased. The main global trends in the development of pharmaceutical markets are observed – consolidation and development of vertically integrated companies. Changes are taking place in the distribution, manufacturing and retail sectors. The number of pharmacy chains is increasing. Modern marketing technologies are being introduced. Also, the pharmaceutical market of Kazakhstan among the Central Asian countries remains the most accessible and transparent for foreign manufacturers from the point of view of the legislative environment. However, the potential of the market is limited by the relatively small number and purchasing power of the population. The growth of the pharmaceutical industry will continue to be driven mainly by demand for generic drugs. Kazakhstan's integration into the EAEU will contribute to improving the quality of medicines and reducing their cost. The purpose of this article is to analyze the development and state regulation of pharmaceutical companies in the Republic of Kazakhstan, identify problems in the field of regulation of pharmaceutical companies in the Republic of Kazakhstan and ways to solve them. Methods: The methodological basis of the research is a comprehensive analysis of the general industry, namely the pharmaceutical industry within the framework of the implementation of the State Program of Industrial and Innovative Development of the Republic of Kazakhstan. Results and their significance: Authors in his article are described the development of the pharmaceutical market in Kazakhstan and analyzes the results in recent years. The authors also considered the main aspects of the development of the pharmaceutical industry within the framework of the implementation of the State Program of industrial and innovative development of the Republic of Kazakhstan for 2020-2025. A review analysis of literary sources was used in the study. During the analysis of the domestic industrial market, namely the component part of which is the pharmaceutical industry, authors found out a number of problems faced by manufacturers. Namely, the absence of ethical commissions, increased value added tax.